Sheaff Brock Investment Advisors LLC Boosts Stake in Clovis Oncology, Inc. (CLVS)

Sheaff Brock Investment Advisors LLC increased its holdings in Clovis Oncology, Inc. (NASDAQ:CLVS) by 19.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,225 shares of the biopharmaceutical company’s stock after buying an additional 700 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Clovis Oncology were worth $396,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Aperio Group LLC boosted its holdings in shares of Clovis Oncology by 1.7% in the 2nd quarter. Aperio Group LLC now owns 5,093 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 83 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of Clovis Oncology by 3.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 100 shares during the period. Clough Capital Partners L P boosted its holdings in shares of Clovis Oncology by 0.6% in the 1st quarter. Clough Capital Partners L P now owns 15,900 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 100 shares during the period. Greenwood Capital Associates LLC boosted its holdings in shares of Clovis Oncology by 4.0% in the 2nd quarter. Greenwood Capital Associates LLC now owns 5,485 shares of the biopharmaceutical company’s stock valued at $514,000 after buying an additional 212 shares during the period. Finally, Prudential Financial Inc. boosted its holdings in shares of Clovis Oncology by 15.5% in the 2nd quarter. Prudential Financial Inc. now owns 4,388 shares of the biopharmaceutical company’s stock valued at $411,000 after buying an additional 590 shares during the period. 98.94% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently commented on CLVS shares. J P Morgan Chase & Co raised shares of Clovis Oncology from a “neutral” rating to an “overweight” rating and set a $72.00 price target for the company in a report on Wednesday, May 17th. Bank of America Corporation reaffirmed a “buy” rating and issued a $75.00 price target on shares of Clovis Oncology in a report on Wednesday, May 17th. ValuEngine lowered shares of Clovis Oncology from a “hold” rating to a “sell” rating in a report on Friday, May 19th. Leerink Swann started coverage on shares of Clovis Oncology in a report on Tuesday, June 13th. They issued an “outperform” rating and a $85.00 price target for the company. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $88.00 price target on shares of Clovis Oncology in a report on Friday, June 16th. Eight research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Clovis Oncology presently has a consensus rating of “Buy” and a consensus target price of $85.16.

Shares of Clovis Oncology, Inc. (NASDAQ:CLVS) opened at 67.17 on Monday. The firm’s market capitalization is $3.28 billion. The stock has a 50 day moving average of $76.78 and a 200-day moving average of $68.43. Clovis Oncology, Inc. has a 52 week low of $25.50 and a 52 week high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by $0.02. The business had revenue of $14.62 million for the quarter, compared to analysts’ expectations of $13.07 million. During the same quarter in the prior year, the company posted ($2.07) earnings per share. The firm’s revenue was down 32.5% on a year-over-year basis. Analysts expect that Clovis Oncology, Inc. will post ($7.53) earnings per share for the current year.

In other Clovis Oncology news, Director James C. Blair sold 18,450 shares of the stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the sale, the director now owns 2,185 shares of the company’s stock, valued at approximately $171,762.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $91.56, for a total transaction of $274,680.00. Following the sale, the insider now directly owns 197,583 shares in the company, valued at approximately $18,090,699.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,450 shares of company stock worth $2,120,645. Insiders own 17.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Sheaff Brock Investment Advisors LLC Boosts Stake in Clovis Oncology, Inc. (CLVS)” was published by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2017/09/11/sheaff-brock-investment-advisors-llc-boosts-stake-in-clovis-oncology-inc-clvs.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology, Inc. (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply